ATLANTA, Feb. 24, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that management will be attending the following investor conferences in March:
- The Citi 2011 Global Health Care Conference to be held March 1-3, 2011 at The Hilton New York Hotel in New York City. Dan Myers, president and chief executive officer, is scheduled to present on March 2 at 2:30 P.M. ET.
- The Credit Suisse One-on-One Healthcare Conference to be held March 1-3, 2011 in London, UK. Rick Eiswirth, chief operating officer and chief financial officer, will be meeting with investors on March 2-3.
- The 2011 RBC Capital Markets' Healthcare Conference to be held March 2-3, 2011 at The New York Palace Hotel in New York City. Mr. Myers is scheduled to present on March 3 at 2:00 PM ET.
- The Cowen and Company 31st Annual Health Care Conference to be held March 7-9, 2011 at The Boston Marriott Copley Place in Boston, MA. Mr. Myers is scheduled to present on March 7 at 1:00 PM ET.
The presentations will be webcast live and can be accessed on the Investor Relations section of the corporate website at http://www.alimerasciences.com . For those who are not available to listen to the live broadcasts, the presentations will be archived for two weeks.
About Alimera Sciences, Inc.Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN® is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. A New Drug Application for ILUVIEN® is currently under review by the US Food and Drug Administration. The FDA, in a December 2010 Complete Response Letter, requested further information including the month 36 data from the FAME Study.
CONTACT: ICR, LLC for Alimera Sciences John Mills 310-954-1105 John.Mills@icrinc.com